Raymond James & Associates increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) by 131.0% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 27,916 shares of the medical equipment provider’s stock after acquiring an additional 15,830 shares during the period. Raymond James & Associates’ holdings in Lantheus were worth $1,963,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. FinTrust Capital Advisors LLC bought a new position in shares of Lantheus in the 2nd quarter valued at about $26,000. Dupont Capital Management Corp acquired a new stake in Lantheus in the 2nd quarter valued at about $32,000. Focused Wealth Management Inc bought a new position in Lantheus during the third quarter worth about $63,000. Spire Wealth Management acquired a new position in Lantheus during the second quarter worth approximately $119,000. Finally, Fairfield Bush & CO. bought a new stake in Lantheus in the first quarter valued at approximately $177,000. 97.62% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on LNTH. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Friday, November 4th. Mizuho initiated coverage on shares of Lantheus in a research report on Wednesday, October 12th. They issued a “buy” rating and a $105.00 price objective on the stock. Jonestrading assumed coverage on shares of Lantheus in a report on Thursday, October 6th. They set a “buy” rating and a $104.00 target price for the company. Finally, SVB Leerink assumed coverage on shares of Lantheus in a report on Wednesday, November 30th. They issued an “outperform” rating on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $102.80.
Lantheus Price Performance
Lantheus (NASDAQ:LNTH – Get Rating) last posted its quarterly earnings data on Thursday, November 3rd. The medical equipment provider reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.15. The firm had revenue of $239.29 million for the quarter, compared to analyst estimates of $228.52 million. Lantheus had a return on equity of 37.77% and a net margin of 13.35%. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 3.53 earnings per share for the current year.
Insider Activity at Lantheus
In other Lantheus news, COO Paul Blanchfield sold 2,432 shares of the firm’s stock in a transaction dated Thursday, November 17th. The shares were sold at an average price of $54.79, for a total value of $133,249.28. Following the transaction, the chief operating officer now directly owns 73,968 shares of the company’s stock, valued at approximately $4,052,706.72. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Lantheus news, COO Paul Blanchfield sold 2,432 shares of the company’s stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $54.79, for a total transaction of $133,249.28. Following the completion of the sale, the chief operating officer now directly owns 73,968 shares in the company, valued at $4,052,706.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Daniel Niedzwiecki sold 3,000 shares of Lantheus stock in a transaction on Friday, November 11th. The shares were sold at an average price of $59.73, for a total value of $179,190.00. Following the completion of the transaction, the insider now owns 65,143 shares in the company, valued at approximately $3,890,991.39. The disclosure for this sale can be found here. Insiders sold a total of 19,354 shares of company stock valued at $1,105,945 over the last quarter. 1.60% of the stock is owned by corporate insiders.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.